An announcement from Resonance Health Ltd ( (AU:RHT) ) is now available.
Resonance Health Limited reported a 60% increase in revenues from ordinary activities, reaching $5,210,477 for the half-year ended 31 December 2024. Despite this growth in revenue, the company experienced an 86% increase in loss from ordinary activities after tax, amounting to $1,036,192. The financial results included an income tax benefit due to the R&D tax incentive refund, which highlights the company’s ongoing investment in research and development. The net tangible assets per ordinary security decreased, indicating a potential concern for stakeholders regarding the company’s asset management.
More about Resonance Health Ltd
Resonance Health Limited operates in the healthcare industry, focusing on medical imaging software and services. The company is known for its expertise in developing non-invasive imaging solutions for the diagnosis and management of human diseases, with a particular emphasis on liver health.
YTD Price Performance: 16.00%
Average Trading Volume: 247,167
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$26.66M
For a thorough assessment of RHT stock, go to TipRanks’ Stock Analysis page.